AbbVie Inc.

ABBV

US00287Y1091

AbbVie Inc. specializes in therapeutic drug research and development. Its products are intended for treating rheumatoid arthritis, psoriasis, Crohn's disease, thyroid disease, Parkinson's disease, HIV, complications of mucoviscidosis, low testosterone levels, and complications associated with chronic renal disease. Net sales are distributed geographically as follows: the United States (78.7%), Germany (2.3%), Canada (2%), Japan (1.6%), China (1.6%), France (1.4%), Australia (0.9%), Spain (0.9%), the United Kingdom (0.8%), Italy (0.8%), Brazil (0.7%) and other (8.3%).

Sector

Pharmaceuticals

Calendar

09:00am - Acquisition of Cerevel Therapeutics by AbbVie Inc Call

More about the company

Income Statement Evolution

More financial data

Ratings for AbbVie Inc.

Trading Rating :

Investor Rating :

ESG Refinitiv :

C+

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

OUTPERFORM

Number of Analysts

Last Close Price

146.38USD

Average target price

167.53USD

Spread / Average Target

+14.45%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Pharmaceuticals

	1st Jan change	Capi.
ABBVIE INC.	-8.62%	258 B $
ELI LILLY AND COMPANY	+60.11%	530 B $
NOVO NORDISK A/S	+42.05%	438 B $
JOHNSON & JOHNSON	-11.63%	377 B $
MERCK & CO., INC.	-5.96%	268 B $
ROCHE HOLDING AG	-14.13%	230 B $
NOVARTIS AG	+0.79%	200 B $
ASTRAZENECA PLC	-9.98%	198 B $
PFIZER, INC.	-43.75%	163 B $
AMGEN INC.	+3.59%	144 B $

Other Pharmaceuticals

Real-time Estimate Cboe BZX Other stock markets 02:27:15 2023-12-07 pm EST			5-day change	1st Jan Change
147.56 ^USD	+0.81%		+3.72%	-8.62%

07:54pm	Sector Update: Health Care Stocks Drop Thursday Afternoon	MT
07:42pm	AbbVie-Cerevel Deal Makes 'Strategic Sense,' Mizuho Says	MT

Sector Update: Health Care Stocks Drop Thursday Afternoon	01:54pm	MT
AbbVie-Cerevel Deal Makes 'Strategic Sense,' Mizuho Says	01:42pm	MT
Sector Update: Health Care	01:35pm	MT
AbbVie's $8.7 bln bet on Cerevel is risky but smart, analysts say	01:30pm	RE
Bain scores over tenfold return with $8.7 billion Cerevel sale	12:35pm	RE
Global markets live: AbbVie, McDonald's, Apple, AMD, Alphabet...	12:35pm
Top Stories at Midday: Moody's Downgrades Chinese Banks; AbbVie Acquires Cerevel; Washington to Use March-In Law to Seize Pharma Patents; JetBlue Hikes Outlook	12:04pm	MT
AbbVie to focus on smaller deals after buying spree	11:48am	RE
Biden Administration Launches Measures to Cut Health Care Costs; Proposes Use of 'March-In Rights' for Drugs	10:30am	MT
Trending : AbbVie to Buy Cerevel for $45 a Share	10:13am	DJ
Are rate cuts are coming early next year?	10:10am
Abbvie to focus on smaller deals after Cerevel and ImmunoGen buyout	09:46am	RE
President Biden Announces Health Care Measure to Lower Costs, Promote Competition, 'March-In' Drug Patents on Govt-Funded Research	09:18am	MT
Transcript : AbbVie Inc., Cerevel Therapeutics Holdings, Inc. - M&A Call	09:00am	CI
North American Morning Briefing : Stock Futures Struggle to Extend Rally Ahead of More Jobs Data	06:20am	DJ
AbbVie: acquisition of Cerevel Therapeutics	04:32am	CF
Cerevel options trading surge before AbbVie deal news raises eyebrows	10:33pm	RE
AbbVie to buy drug developer Cerevel for $8.7 billion	06:23pm	RE
Health Flat as Obesity-Drug Stock Craze Eases -- Health Care Roundup	Dec. 06	DJ
AbbVie Signs $8.7 Billion Deal to Acquire Cerevel Therapeutics	Dec. 06	MT
AbbVie Signs Deal to Buy Cerevel Therapeutics for $45/Share Cash, or Total Equity Value of About $8.7 Billion; Deal Seen Adding to AbbVie Earnings Beginning in 2030	Dec. 06	MT
AbbVie Reportedly Near Deal to Acquire Cerevel Therapeutics, According to Reuters; AbbVie Could Pay About $45 Per Share for Cerevel, Report Says	Dec. 06	MT
AbbVie to Buy Cerevel Therapeutics for $8.7 Billion -- Update	Dec. 06	DJ
AbbVie to Buy Cerevel Therapeutics for $8.7 Billion	Dec. 06	DJ
AbbVie Close to $8 Billion Deal for Cerevel Therapeutics, Sources Say, Reuters Reports	Dec. 06	DJ